BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sawabu N, Watanabe H, Yamaguchi Y, Ohtsubo K, Motoo Y. Serum tumor markers and molecular biological diagnosis in pancreatic cancer. Pancreas 2004;28:263-7. [PMID: 15084968 DOI: 10.1097/00006676-200404000-00009] [Cited by in Crossref: 50] [Cited by in F6Publishing: 43] [Article Influence: 2.9] [Reference Citation Analysis]
Number Citing Articles
1 Friess H, Ho C, Kleeff J, Büchler M. Pancreaticoduodenectomy, Distal Pancreatectomy, Segmental Pancreatectomy, Total Pancreatectomy, and Transduodenal Resection of the Papilla of Vater. Surgery of the Liver, Biliary Tract and Pancreas. Elsevier; 2007. pp. 877-903. [DOI: 10.1016/b978-1-4160-3256-4.50068-5] [Cited by in Crossref: 7] [Article Influence: 0.5] [Reference Citation Analysis]
2 Ni XG, Bai XF, Mao YL, Shao YF, Wu JX, Shan Y, Wang CF, Wang J, Tian YT, Liu Q. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer. Eur J Surg Oncol. 2005;31:164-169. [PMID: 15698733 DOI: 10.1016/j.ejso.2004.09.007] [Cited by in Crossref: 158] [Cited by in F6Publishing: 151] [Article Influence: 9.9] [Reference Citation Analysis]
3 Shore S, Vimalachandran D, Raraty MG, Ghaneh P. Cancer in the elderly: pancreatic cancer. Surgical Oncology 2004;13:201-10. [DOI: 10.1016/j.suronc.2004.11.001] [Cited by in Crossref: 38] [Cited by in F6Publishing: 30] [Article Influence: 2.2] [Reference Citation Analysis]
4 Haraguchi K, Sato S, Habu M, Yada N, Hayakawa M, Takahashi O, Yoshioka I, Matsuo K, Tominaga K, Takenaka S. Oral Cancer Screening Based on Methylation Frequency Detection in hTERT Gene Using Electrochemical Hybridization Assay via a Multi-electrode Chip Coupled with Ferrocenylnaphthalene Diimide. Electroanalysis 2017;29:1596-601. [DOI: 10.1002/elan.201700028] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
5 Takehara A, Eguchi H, Ohigashi H, Ishikawa O, Kasugai T, Hosokawa M, Katagiri T, Nakamura Y, Nakagawa H. Novel tumor marker REG4 detected in serum of patients with resectable pancreatic cancer and feasibility for antibody therapy targeting REG4. Cancer Sci. 2006;97:1191-1197. [PMID: 16918991 DOI: 10.1111/j.1349-7006.2006.00297.x] [Cited by in Crossref: 60] [Cited by in F6Publishing: 50] [Article Influence: 4.0] [Reference Citation Analysis]
6 Okada G, Watanabe H, Ohtsubo K, Mouri H, Yamaguchi Y, Motoo Y, Sawabu N. Multiple factors influencing the release of hTERT mRNA from pancreatic cancer cell lines in in vitro culture. Cell Biol Int 2012;36:545-53. [PMID: 21080909 DOI: 10.1042/CBI20090471] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
7 Michl P, Pauls S, Gress TM. Evidence-based diagnosis and staging of pancreatic cancer. Best Pract Res Clin Gastroenterol. 2006;20:227-251. [PMID: 16549326 DOI: 10.1016/j.bpg.2005.10.005] [Cited by in Crossref: 83] [Cited by in F6Publishing: 50] [Article Influence: 5.5] [Reference Citation Analysis]
8 Parsons BL, Meng F. K-RAS mutation in the screening, prognosis and treatment of cancer. Biomark Med 2009;3:757-69. [PMID: 20477713 DOI: 10.2217/bmm.09.95] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 2.5] [Reference Citation Analysis]
9 Shadhu K, Xi C. Inflammation and pancreatic cancer: An updated review. Saudi J Gastroenterol 2019;25:3-13. [PMID: 30588953 DOI: 10.4103/sjg.SJG_390_18] [Cited by in Crossref: 18] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
10 Takahasi K, Iinuma H, Wada K, Minezaki S, Kawamura S, Kainuma M, Ikeda Y, Shibuya M, Miura F, Sano K. Usefulness of exosome-encapsulated microRNA-451a as a minimally invasive biomarker for prediction of recurrence and prognosis in pancreatic ductal adenocarcinoma. J Hepatobiliary Pancreat Sci. 2018;25:155-161. [PMID: 29130611 DOI: 10.1002/jhbp.524] [Cited by in Crossref: 49] [Cited by in F6Publishing: 47] [Article Influence: 16.3] [Reference Citation Analysis]
11 Ozkan H, Akar T, Köklü S, Coban S. Significance of serum receptor-binding cancer antigen (RCAS1) in pancreatic cancer and benign pancreatobiliary diseases. Pancreatology 2006;6:268-72. [PMID: 16636598 DOI: 10.1159/000092687] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
12 Taylor AD, Hancock WS, Hincapie M, Taniguchi N, Hanash SM. Towards an integrated proteomic and glycomic approach to finding cancer biomarkers. Genome Med 2009;1:57. [PMID: 19519948 DOI: 10.1186/gm57] [Cited by in Crossref: 55] [Cited by in F6Publishing: 43] [Article Influence: 4.6] [Reference Citation Analysis]
13 Boeck S, Stieber P, Holdenrieder S, Wilkowski R, Heinemann V. Prognostic and Therapeutic Significance of Carbohydrate Antigen 19-9 as Tumor Marker in Patients with Pancreatic Cancer. Oncology 2006;70:255-64. [DOI: 10.1159/000094888] [Cited by in Crossref: 100] [Cited by in F6Publishing: 94] [Article Influence: 6.7] [Reference Citation Analysis]
14 Su SB, Qin SY, Chen W, Luo W, Jiang HX. Carbohydrate antigen 19-9 for differential diagnosis of pancreatic carcinoma and chronic pancreatitis. World J Gastroenterol 2015;21:4323-33. [PMID: 25892884 DOI: 10.3748/wjg.v21.i14.4323] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 17] [Article Influence: 4.6] [Reference Citation Analysis]
15 Hwang TL, Liang Y, Chien KY, Yu JS. Overexpression and elevated serum levels of phosphoglycerate kinase 1 in pancreatic ductal adenocarcinoma. Proteomics. 2006;6:2259-2272. [PMID: 16493704 DOI: 10.1002/pmic.200500345] [Cited by in Crossref: 92] [Cited by in F6Publishing: 82] [Article Influence: 6.1] [Reference Citation Analysis]
16 Ishikawa M, Yoshida K, Yamashita Y, Ota J, Takada S, Kisanuki H, Koinuma K, Choi YL, Kaneda R, Iwao T, Tamada K, Sugano K, Mano H. Experimental trial for diagnosis of pancreatic ductal carcinoma based on gene expression profiles of pancreatic ductal cells. Cancer Sci 2005;96:387-93. [PMID: 16053509 DOI: 10.1111/j.1349-7006.2005.00064.x] [Cited by in Crossref: 56] [Cited by in F6Publishing: 50] [Article Influence: 3.5] [Reference Citation Analysis]
17 Mortoglou M, Tabin ZK, Arisan ED, Kocher HM, Uysal-Onganer P. Non-coding RNAs in pancreatic ductal adenocarcinoma: New approaches for better diagnosis and therapy. Transl Oncol 2021;14:101090. [PMID: 33831655 DOI: 10.1016/j.tranon.2021.101090] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
18 Sandblom G, Granroth S, Rasmussen IC. TPS, CA 19-9, VEGF-A, and CEA as diagnostic and prognostic factors in patients with mass lesions in the pancreatic head. Ups J Med Sci. 2008;113:57-64. [PMID: 18521799 DOI: 10.3109/2000-1967-214] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 1.8] [Reference Citation Analysis]
19 Kumar Y, Tapuria N, Kirmani N, Davidson BR. Tumour M2-pyruvate kinase: a gastrointestinal cancer marker. Eur J Gastroenterol Hepatol. 2007;19:265-276. [PMID: 17301655 DOI: 10.1097/meg.0b013e3280102f78] [Cited by in Crossref: 53] [Cited by in F6Publishing: 20] [Article Influence: 3.8] [Reference Citation Analysis]
20 Gao YC, Yuan ZB, Yang YD, Lu HK. Effect of freeze-thaw cycles on serum measurements of AFP, CEA, CA125 and CA19-9. Scand J Clin Lab Invest 2007;67:741-7. [PMID: 17852813 DOI: 10.1080/00365510701297480] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
21 Chen YF, Wang JY, Wu CH, Chen FM, Cheng TL, Lin SR. Detection of circulating cancer cells with K-ras oncogene using membrane array. Cancer Lett 2005;229:115-22. [PMID: 16157223 DOI: 10.1016/j.canlet.2004.12.026] [Cited by in Crossref: 44] [Cited by in F6Publishing: 34] [Article Influence: 2.8] [Reference Citation Analysis]
22 Luo G, Liu C, Guo M, Cheng H, Lu Y, Jin K, Liu L, Long J, Xu J, Lu R, Ni Q, Yu X. Potential Biomarkers in Lewis Negative Patients With Pancreatic Cancer. Ann Surg. 2017;265:800-805. [PMID: 28267695 DOI: 10.1097/sla.0000000000001741] [Cited by in Crossref: 52] [Cited by in F6Publishing: 30] [Article Influence: 13.0] [Reference Citation Analysis]
23 Ohtsubo K, Watanabe H, Yao F, Okada G, Mouri H, Yamaguchi Y, Sawabu N. Preproenkephalin hypermethylation in the pure pancreatic juice compared with p53 mutation in the diagnosis of pancreatic carcinoma. J Gastroenterol 2006;41:791-7. [DOI: 10.1007/s00535-006-1857-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
24 Molina V, Visa L, Conill C, Navarro S, Escudero JM, Auge JM, Filella X, Lopez-Boado MA, Ferrer J, Fernandez-Cruz L, Molina R. CA 19-9 in pancreatic cancer: retrospective evaluation of patients with suspicion of pancreatic cancer. Tumour Biol. 2012;33:799-807. [PMID: 22203495 DOI: 10.1007/s13277-011-0297-8] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 2.8] [Reference Citation Analysis]
25 Zhou J, Hu L, Yu Z, Zheng J, Yang D, Bouvet M, Hoffman RM. Marker expression in circulating cancer cells of pancreatic cancer patients. J Surg Res. 2011;171:631-636. [PMID: 20869080 DOI: 10.1016/j.jss.2010.05.007] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 3.2] [Reference Citation Analysis]
26 Talar-Wojnarowska R, Gasiorowska A, Olakowski M, Lekstan A, Lampe P, Malecka-Panas E. Clinical value of serum neopterin, tissue polypeptide-specific antigen and CA19-9 levels in differential diagnosis between pancreatic cancer and chronic pancreatitis. Pancreatology 2010;10:689-94. [PMID: 21242708 DOI: 10.1159/000320693] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
27 Chiang KC, Yeh CN, Lee WC, Jan YY, Hwang TL. Prognostic analysis of patients with pancreatic head adenocarcinoma less than 2 cm undergoing resection. World J Gastroenterol 2009;15:4305-10. [PMID: 19750574 DOI: 10.3748/wjg.15.4305] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
28 Agarwal B, Correa AM, Ho L. Survival in pancreatic carcinoma based on tumor size. Pancreas 2008;36:e15-20. [PMID: 18192868 DOI: 10.1097/mpa.0b013e31814de421] [Cited by in Crossref: 56] [Cited by in F6Publishing: 44] [Article Influence: 4.3] [Reference Citation Analysis]
29 Grochola LF, Greither T, Taubert HW, Möller P, Knippschild U, Udelnow A, Henne-Bruns D, Würl P. Prognostic relevance of hTERT mRNA expression in ductal adenocarcinoma of the pancreas. Neoplasia 2008;10:973-6. [PMID: 18714398 DOI: 10.1593/neo.08578] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
30 Elshimali YI, Khaddour H, Sarkissyan M, Wu Y, Vadgama JV. The clinical utilization of circulating cell free DNA (CCFDNA) in blood of cancer patients. Int J Mol Sci 2013;14:18925-58. [PMID: 24065096 DOI: 10.3390/ijms140918925] [Cited by in Crossref: 151] [Cited by in F6Publishing: 120] [Article Influence: 18.9] [Reference Citation Analysis]
31 Niikura K, Kamitani R, Kurogochi M, Uematsu R, Shinohara Y, Nakagawa H, Deguchi K, Monde K, Kondo H, Nishimura S. Versatile Glycoblotting Nanoparticles for High-Throughput Protein Glycomics. Chem Eur J 2005;11:3825-34. [DOI: 10.1002/chem.200401289] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 1.7] [Reference Citation Analysis]
32 Jiang P, Watanabe H, Okada G, Ohtsubo K, Mouri H, Tsuchiyama T, Yao F, Sawabu N. Diagnostic utility of aberrant methylation of tissue factor pathway inhibitor 2 in pure pancreatic juice for pancreatic carcinoma. Cancer Science 2006;97:1267-73. [DOI: 10.1111/j.1349-7006.2006.00308.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
33 Parikh DA, Durbin-Johnson B, Urayama S. Utility of serum CA19-9 levels in the diagnosis of pancreatic ductal adenocarcinoma in an endoscopic ultrasound referral population. J Gastrointest Cancer 2014;45:74-9. [PMID: 24272911 DOI: 10.1007/s12029-013-9563-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
34 Jung KW, Kim MH, Lee TY, Kwon S, Oh HC, Lee SS, Seo DW, Lee SK. Clinicopathological aspects of 542 cases of pancreatic cancer: a special emphasis on small pancreatic cancer. J Korean Med Sci 2007;22 Suppl:S79-85. [PMID: 17923760 DOI: 10.3346/jkms.2007.22.S.S79] [Cited by in Crossref: 20] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
35 Fry LC, Mönkemüller K, Malfertheiner P. Molecular markers of pancreatic cancer: development and clinical relevance. Langenbecks Arch Surg. 2008;393:883-890. [PMID: 18266003 DOI: 10.1007/s00423-007-0276-0] [Cited by in Crossref: 39] [Cited by in F6Publishing: 32] [Article Influence: 3.0] [Reference Citation Analysis]
36 Liu MP, Guo XZ, Xu JH, Wang D, Li HY, Cui ZM, Zhao JJ, Ren LN. New tumor-associated antigen SC6 in pancreatic cancer. World J Gastroenterol 2005;11:7671-5. [PMID: 16437697 DOI: 10.3748/wjg.v11.i48.7671] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
37 Verma M. Pancreatic cancer epidemiology. Technol Cancer Res Treat. 2005;4:295-301. [PMID: 15896085 DOI: 10.1177/153303460500400309] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 0.9] [Reference Citation Analysis]
38 Wang Y, Xu Z, Zhou F, Sun Y, Chen J, Li L, Jin H, Qian Q. The combination of dendritic cells-cytotoxic T lymphocytes/cytokine-induced killer (DC-CTL/CIK) therapy exerts immune and clinical responses in patients with malignant tumors. Exp Hematol Oncol 2015;4:32. [PMID: 26561538 DOI: 10.1186/s40164-015-0027-9] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
39 Rashid S, Singh N, Gupta S, Rashid S, Nalika N, Sachdev V, Bal CS, Datta Gupta S, Chauhan SS, Saraya A. Progression of Chronic Pancreatitis to Pancreatic Cancer: Is There a Role of Gene Mutations as a Screening Tool? Pancreas. 2018;47:227-232. [PMID: 29303908 DOI: 10.1097/mpa.0000000000000975] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
40 Lennon AM, Goggins M. Diagnostic and Therapeutic Response Markers. Pancreatic Cancer. New York: Springer; 2010. pp. 675-701. [DOI: 10.1007/978-0-387-77498-5_28] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
41 Liu S, Chen G, Zhao Y, Wu W, Zhang T. Diagnostic accuracy of K-ras mutation for pancreatic carcinoma: a meta-analysis. Hepatobiliary & Pancreatic Diseases International 2013;12:458-64. [DOI: 10.1016/s1499-3872(13)60073-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
42 Mendieta Zerón H, García Flores JR, Romero Prieto ML. Limitations in improving detection of pancreatic adenocarcinoma. Future Oncol. 2009;5:657-668. [PMID: 19519205 DOI: 10.2217/fon.09.32] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
43 Hoffmann K, Kerner C, Wilfert W, Mueller M, Thiery J, Hauss J, Witzigmann H. Detection of disseminated pancreatic cells by amplification of cytokeratin-19 with quantitative RT-PCR in blood, bone marrow and peritoneal lavage of pancreatic carcinoma patients. World J Gastroenterol 2007;13:257-63. [PMID: 17226905 DOI: 10.3748/wjg.v13.i2.257] [Cited by in CrossRef: 47] [Cited by in F6Publishing: 39] [Article Influence: 3.4] [Reference Citation Analysis]